The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

The FDA suggests that prescribed users also reduce their calorie intake and increase their exercise The weight loss drug ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Rapid weight loss has been a hallmark of these medications ... to easing knee arthritis pain to curbing asthma. Friday's FDA approval of Zepbound for treating moderate to severe sleep apnea ...

called the FDA’s approval a "promising advancement for the millions of people who suffer from this condition." "Zepbound promotes weight loss and has been shown to reduce apnea events." ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

Got a tip? Send it to The Daily Beast here. ADVERTISEMENT ADVERTISEMENT ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

20, the FDA announced that the agency has approved Eli Lilly’s Zepbound ... “Zepbound promotes weight loss and has been shown to reduce apnea events,” Troxel noted.

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...